E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
This study will investigate the modulation of the immune system by Cytomegalovirus (CMV) in ANCA-associated vasculitis.
Specifically the study will investigate the potential for valaciclovir to prevent CMV-mediated adverse modulation of the immune system in patients with ANCA-associated vasculitis. |
|
E.1.1.1 | Medical condition in easily understood language |
This study will investigate the potential for antiviral treatment to prevent the negative effects of Cytomegalovirus (CMV) on the immune system in patients with vasculitis. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Immune System Diseases [C20] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 15.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10011831 |
E.1.2 | Term | Cytomegalovirus infection |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 15.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10050894 |
E.1.2 | Term | Anti-neutrophil cytoplasmic antibody positive vasculitis |
E.1.2 | System Organ Class | 10021428 - Immune system disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Aim 1 To investigate the association between CMV reactivation and the impairment of the function of CMV committed T-cells in ANCA associated vasculitis
Aim 2 To determine whether treatment of ANCA associated vasculitis patients with valaciclovir leads to a reduction in CMV reactivation and improved function of CMV committed T-cells |
|
E.2.2 | Secondary objectives of the trial |
Safety of valaciclovir treatment in ANCA associated vasculitis.
Effects of CMV on the immune system in patients with ANCA associated vasculitis patients.
Effects of valaciclovir on the immune response in ANCA associated vasculitis patients. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Documented diagnosis of ANCA associated vasculitis • In stable remission (no documented clinical disease activity) for at least 6 months prior to entry. • On maintenance immunosuppression with maximum 2 agents. • Documented evidence of CMV infection. • Documentation that female patients of child bearing age are not pregnant. • Written informed consent for study participation
|
|
E.4 | Principal exclusion criteria |
• Severe chronic kidney disease (Stage 5). • Other significant chronic infection (HIV, HBV, HCV, TB). • B-cell or T-cell depleting therapy within 12 months. • Treatment with anti-CMV therapies in last month • Underlying medical conditions, which in the opinion of the Investigator place the patient at unacceptably high risk for participating in the study. • Inability to fully or appropriately participate in the study.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
• Proportion of patients with CMV reactivation, as assessed by measurable viral load on quantitative blood or urine CMV testing by PCR technique. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Primary timepoint At end of 6-month treatment with valaciclovir.
Secondary timepoint At 6 months follow up post cessation of treatment with valaciclovir.
|
|
E.5.2 | Secondary end point(s) |
• Safety as defined by side effects sufficient to stop treatment with trial drugs or serious adverse events and suspected unexpected serious adverse reactions (SUSARs). • Change in the immune characteristics of the CMV 'committed' T cell population • Change in markers of inflammation in the blood • Persistence of valaciclovir effect on immune characteristics of T cells |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Primary timepoint At end of 6-month treatment with valaciclovir.
Secondary timepoint At 6 months follow up post cessation of treatment with valaciclovir.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 9 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 9 |
E.8.9.2 | In all countries concerned by the trial days | 0 |